Summit Therapeutics (SMMT) AI Stock Analysis

• Market Cap: $11.72B
• Dividend Yield: N/A
• Average Volume (3M): 2.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.53
• Revenue Growth: N/A
• EPS Growth: -348.63%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 775,372,700
• 10 Day Avg. Volume: 1,889,403
• 30 Day Avg. Volume: 2,502,301
• PEG Ratio: -0.03
• Price to Book (P/B): 19.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -40.41
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -103.83K
• Enterprise Value/Ebitda: -14.04
• 1Y Price Target: $31.78
• Price Target Upside: 106.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -1.06
• Revenue Forecast (FY): $5.47M

• Rating: 54 Neutral
• Price Target: $16.50 ▲(7.28% Upside)
• Action: Reiterated Date: 02/24/26
• Date: Action: Reiterated 02/24/26

The score is held back primarily by very weak operating performance (minimal revenue with accelerating losses and cash burn) and limited valuation support (negative P/E, no dividend). Offsetting these are a strong balance sheet (low leverage, substantial cash) and a constructive earnings call with clear clinical/regulatory milestones, while technicals remain mixed and not yet supportive of a sustained uptrend.

Positive Factors

Strong balance sheet

A cash balance of ~$713M with no debt materially extends Summit's runway to fund late‑stage trials, regulatory filings, and initial commercial readiness without immediate financing. This reduces near‑term solvency risk and gives management flexibility to fund pivotal OS analyses and launch investments.

Clinical momentum and regulatory progress

Multiple positive Phase III readouts, two China approvals, and an FDA BLA acceptance with a set PDUFA date mark durable progress from development to potential commercialization. These milestones materially de‑risk the program relative to earlier phases and support future partner interest and launch planning if OS data meets regulators' thresholds.

Manufacturing, collaborations and broad development footprint

Transferring and validating U.S. manufacturing supports timely supply for a potential U.S. launch and lowers operational execution risk. High‑profile collaborations and a broad global trial network accelerate combo strategies, diversify development pathways, and increase trial enrollment speed and external validation of the asset.

Negative Factors

Heavy cash burn and widening losses

Sustained negative free cash flow and a sharply larger 2025 net loss materially increase the firm's reliance on external financing, milestones, or partnerships to fund operations. Over 2–6 months this creates dilution risk, constrains optionality for additional trials, and pressures timing for commercialization investments absent approvals or deal proceeds.

Regulatory requirement for overall survival

An explicit FDA requirement for statistically significant OS raises the bar for U.S. approval and ties commercial outcomes to mature survival data. OS immaturity at interim PFS readouts increases approval uncertainty and could force longer follow‑up or additional trials, delaying revenue realization and increasing development costs.

Dependence on partner/China data for evidence

Relying heavily on partner‑sponsored and China‑origin data introduces regulatory and commercial translation risk for U.S./EU filings. Bridging requirements, population differences, and data provenance questions can complicate submissions, necessitate additional analyses or trials, and slow global labeling and market access even with strong local results.

Summit Therapeutics Business Overview & Revenue Model

Company Description

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Summit Therapeutics generates revenue primarily through collaboration and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the commercial success of the developed products. Additionally, the company may receive government grants and funding from nonprofit organizations that support research and development of new antibiotics. As a clinical-stage company, Summit Therapeutics does not yet generate revenue from product sales, as its products are still in the development phase.

Summit Therapeutics Financial Statement Overview

Summary

Overall fundamentals are weak due to effectively zero revenue and sharply worsening losses and cash burn in 2025 (net loss ~$1.08B; operating/free cash flow ~-$323M). The balance sheet is a key offset with low leverage and higher equity, reducing near-term solvency risk but not eliminating execution/financing risk.

Income Statement

The income statement is very weak: revenue is effectively zero in recent years (including 2025), while losses have expanded materially (net loss of about $1.08B in 2025 vs. $221M in 2024). Profitability is consistently negative, reflecting a pre-commercial biotech profile with a cost base far ahead of revenue generation. A modest positive is that losses were lower in 2024 than 2023, but the sharp deterioration in 2025 dominates the trajectory.

Balance Sheet

The balance sheet looks strong and significantly de-risked versus earlier years. Leverage is currently low (debt-to-equity ~0.03 in 2025) and equity has grown substantially (about $659M in 2025 vs. $389M in 2024), supporting a much larger asset base. Key weakness is that returns on equity have been deeply negative historically due to large net losses, and the business still relies on its capital base to fund operations.

Cash Flow

Cash flow remains pressured by heavy cash burn: operating and free cash flow were roughly -$323M in 2025, worsening from about -$142M in 2024. Free cash flow is consistently negative, indicating ongoing funding needs until commercialization or partnership revenues scale. A relative positive is that free cash flow broadly tracks net income (loss) rather than showing large non-cash distortions, but the direction of burn is unfavorable.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	704.29K	1.81M
Gross Profit	-108.36K	-15.01M	-2.05M	-1.81M	1.81M
EBITDA	-801.12M	-212.85M	-69.45M	-73.12M	-85.91M
Net Income	-1.08B	-221.31M	-614.93M	-78.78M	-88.60M
Balance Sheet
Total Assets	751.18M	435.56M	202.95M	664.17M	113.37M
Cash, Cash Equivalents and Short-Term Investments	713.45M	412.35M	186.24M	348.61M	71.79M
Total Debt	15.50M	7.22M	106.10M	518.76M	2.78M
Total Liabilities	92.32M	46.81M	125.26M	537.51M	30.09M
Stockholders Equity	658.86M	388.75M	77.69M	126.65M	83.28M
Cash Flow
Free Cash Flow	-323.59M	-142.25M	-76.89M	-42.21M	-72.89M
Operating Cash Flow	-322.93M	-142.11M	-76.76M	-41.58M	-72.59M
Investing Cash Flow	-174.31M	-205.34M	-587.77M	-624.00K	-306.00K
Financing Cash Flow	617.53M	381.23M	86.51M	620.24M	77.92M

Summit Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMMT, the sentiment is Negative. The current price of 15.38 is below the 20-day moving average (MA) of 15.43, below the 50-day MA of 16.45, and below the 200-day MA of 20.44, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 27.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMMT.

Summit Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	86 Outperform	$21.48B	16.17	19.71%	―	13.50%	17.16%
INCY	83 Outperform	$19.52B	14.98	29.87%	―	18.09%	3563.21%
GMAB	66 Neutral	$16.94B	19.82	17.65%	―	24.98%	127.06%
ASND	57 Neutral	$14.68B	-50.22	―	―	103.32%	47.55%
SMMT	54 Neutral	$11.72B	-12.11	-206.10%	―	―	-348.63%
BNTX	53 Neutral	$24.23B	-175.05	-2.94%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Summit Therapeutics Corporate Events

Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs

On February 23, 2026, Summit Therapeutics reported its fourth-quarter and full-year 2025 results, highlighting rapid advancement of ivonescimab across a broad Phase III oncology program and multiple collaborations. The company’s global HARMONi-3 Phase III study in first-line metastatic NSCLC has completed screening for the squamous cohort, with an interim progression-free survival analysis planned in the second quarter of 2026 and final PFS data expected in the second half of 2026, while enrollment of the non-squamous cohort is slated to complete in the second half of 2026 with final PFS analysis anticipated in the first half of 2027.

Summit detailed the forthcoming GORTEC-sponsored Phase III ILLUMINE trial in PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma, expected to begin enrolling roughly 780 patients in early second quarter 2026 to compare ivonescimab-based regimens against pembrolizumab monotherapy. The company also noted that the U.S. FDA accepted its BLA for ivonescimab plus chemotherapy in previously treated EGFR-mutated non-squamous NSCLC, setting a PDUFA goal date of November 14, 2026, underscoring a potential near-term commercialization pathway that could reshape its revenue profile if approved.

Operationally, Summit is expanding ivonescimab’s reach through a June 2025 clinical collaboration with Revolution Medicines, where patient enrollment began in first quarter 2026 to test combinations with RAS(ON) inhibitors in RAS-mutant solid tumors, and a January 2026 collaboration with GSK to evaluate combinations with B7-H3 antibody risvutatug rezetecan starting mid-2026. The company continues to support over 60 investigator-sponsored trials, including at major cancer centers such as MD Anderson, Memorial Sloan Kettering, and Dana-Farber, positioning ivonescimab as a broadly investigated backbone therapy in solid tumors.

Financially, Summit ended 2025 with $713.4 million in cash, cash equivalents, and short-term investments, up from $412.3 million a year earlier, providing substantial runway for its late-stage pipeline. GAAP operating expenses surged to $1.09 billion in 2025 from $226.0 million in 2024, driven largely by $681.4 million of additional stock-based compensation tied to performance-based option modifications, while non-GAAP operating expenses nearly doubled to $362.0 million, reflecting substantial clinical expansion and escalating development costs for ivonescimab.

The most recent analyst rating on (SMMT) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.

Summit Therapeutics’ Ivonescimab BLA Accepted by FDA

On January 29, 2026, Summit Therapeutics announced that the U.S. Food & Drug Administration accepted for filing its Biologics License Application for ivonescimab in combination with chemotherapy for patients with EGFR‑mutated locally advanced or metastatic non-squamous non-small cell lung cancer who have progressed after third-generation tyrosine kinase inhibitor therapy. The application, supported by results from the global Phase III HARMONi trial, has been assigned a Prescription Drug User Fee Act goal action date of November 14, 2026, and targets a setting with a significant unmet need, with more than 14,000 eligible U.S. patients annually. Ivonescimab, a novel bispecific antibody that blocks PD‑1 and VEGF, has been tested in numerous Phase III studies worldwide, including multiple Summit-sponsored global trials in lung and colorectal cancers, and already has commercial experience in China through partner Akeso, positioning Summit as a potential new competitor in the U.S. oncology market if approval is granted.

The most recent analyst rating on (SMMT) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.

Summit Therapeutics Expands Ivonescimab Program With GSK Collaboration

On January 12, 2026, Summit Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference and disclosed that it had submitted a Biologics License Application in the fourth quarter of 2025 to the U.S. Food and Drug Administration for ivonescimab in combination with chemotherapy as a second-line or later treatment for patients with epidermal growth factor receptor-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer, underscoring a key regulatory milestone for its lead asset in the U.S. market. On the same date, the company announced a clinical trial collaboration with GSK to evaluate ivonescimab in combination with GSK’s investigational B7-H3–targeting antibody-drug conjugate risvutatug rezetecan across multiple solid tumor settings, including small cell lung cancer, a move that expands ivonescimab’s development footprint and strengthens Summit’s strategic positioning in global oncology through high-profile partnerships and broader combination-therapy opportunities for cancer patients.

The most recent analyst rating on (SMMT) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.